Cargando…

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea

BACKGROUND/AIMS: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Cheolsu, Lee, Ho Sup, Min, Chang-Ki, Lee, Je Jung, Kim, Kihyun, Yoon, Dok Hyun, Eom, Hyeon Seok, Lee, Hyewon, Lee, Won Sik, Shin, Ho-Jin, Lee, Ji Hyun, Park, Yong, Jo, Jae-Cheol, Do, Young Rok, Mun, Yeung-Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578032/ https://www.ncbi.nlm.nih.gov/pubmed/26354062 http://dx.doi.org/10.3904/kjim.2015.30.5.675

Ejemplares similares

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
por: Kwon, Jihyun, et al.
Publicado: (2016)

Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea
por: Lee, Ho Sup, et al.
Publicado: (2014)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
por: Kang, Myung-Hee, et al.
Publicado: (2010)

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
por: Kim, Hyo Jung, et al.
Publicado: (2015)

Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
por: Lee, Ho Sup, et al.
Publicado: (2013)

Onychopapilloma Presenting as Erythronychia and Leukonychia: Dermoscopic Features of Two Cases in Korea
por: Kim, Minsoo, et al.
Publicado: (2018)

Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population
por: Lee, Ho Sup, et al.
Publicado: (2021)

Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
por: Yi, Jun Ho, et al.
Publicado: (2021)

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
por: Song, Ga-Young, et al.
Publicado: (2022)

The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
por: Chang, Hye Jung, et al.
Publicado: (2011)

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023)

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
por: Song, Ga-Young, et al.
Publicado: (2023)

Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18)F-FDG PET/CT
por: Cho, Hee Jeong, et al.
Publicado: (2021)

Elevated Red Blood Cell Distribution Width as a Simple Prognostic Factor in Patients with Symptomatic Multiple Myeloma
por: Lee, Hyewon, et al.
Publicado: (2014)

Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma
por: Shim, Hyoeun, et al.
Publicado: (2014)

BK channel blocker paxilline attenuates thalidomide-caused synaptic and cognitive dysfunctions in mice
por: Choi, Tae-Yong, et al.
Publicado: (2018)

Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide
por: Kong, Seom Gim, et al.
Publicado: (2022)

Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party
por: Jung, Sung-Hoon, et al.
Publicado: (2022)

Transplant physicians' perceptions of cord blood transplantation in Korea: a questionnaire survey
por: Choi, Byeong Seon, et al.
Publicado: (2014)

Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study
por: Han, Sang Hoon, et al.
Publicado: (2006)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
por: Kim, Min Kyoung, et al.
Publicado: (2017)

Chromothripsis in Treatment Resistance in Multiple Myeloma
por: Lee, Kyoung Joo, et al.
Publicado: (2017)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea
por: Kim, Jin Seok, et al.
Publicado: (2023)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Prevalence and characteristics of livestock-associated methicillin-susceptible Staphylococcus aureus in the pork production chain in Korea
por: Eom, Hong Sik, et al.
Publicado: (2019)

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma
por: Hong, Junshik, et al.
Publicado: (2017)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2020)

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS
por: Ho Yi, Jun, et al.
Publicado: (2023)

South Korea's responses to stop the COVID-19 pandemic
por: Kang, JaHyun, et al.
Publicado: (2020)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response
por: Park, Ho Young, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e7sqlj2dlelucuff4p7t18pa5b